1. Home
  2. MLYS vs PGY Comparison

MLYS vs PGY Comparison

Compare MLYS & PGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • PGY
  • Stock Information
  • Founded
  • MLYS 2019
  • PGY 2016
  • Country
  • MLYS United States
  • PGY United States
  • Employees
  • MLYS N/A
  • PGY N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • PGY Finance: Consumer Services
  • Sector
  • MLYS Health Care
  • PGY Finance
  • Exchange
  • MLYS Nasdaq
  • PGY Nasdaq
  • Market Cap
  • MLYS 1.0B
  • PGY 863.7M
  • IPO Year
  • MLYS 2023
  • PGY N/A
  • Fundamental
  • Price
  • MLYS $15.58
  • PGY $16.44
  • Analyst Decision
  • MLYS Strong Buy
  • PGY Strong Buy
  • Analyst Count
  • MLYS 3
  • PGY 9
  • Target Price
  • MLYS $33.00
  • PGY $21.61
  • AVG Volume (30 Days)
  • MLYS 866.7K
  • PGY 2.6M
  • Earning Date
  • MLYS 05-12-2025
  • PGY 05-07-2025
  • Dividend Yield
  • MLYS N/A
  • PGY N/A
  • EPS Growth
  • MLYS N/A
  • PGY N/A
  • EPS
  • MLYS N/A
  • PGY N/A
  • Revenue
  • MLYS N/A
  • PGY $1,076,961,000.00
  • Revenue This Year
  • MLYS N/A
  • PGY $19.84
  • Revenue Next Year
  • MLYS N/A
  • PGY $13.99
  • P/E Ratio
  • MLYS N/A
  • PGY N/A
  • Revenue Growth
  • MLYS N/A
  • PGY 23.69
  • 52 Week Low
  • MLYS $8.24
  • PGY $8.20
  • 52 Week High
  • MLYS $18.38
  • PGY $19.20
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 54.41
  • PGY 66.97
  • Support Level
  • MLYS $15.45
  • PGY $13.85
  • Resistance Level
  • MLYS $16.11
  • PGY $17.44
  • Average True Range (ATR)
  • MLYS 0.96
  • PGY 0.80
  • MACD
  • MLYS -0.05
  • PGY 0.18
  • Stochastic Oscillator
  • MLYS 51.56
  • PGY 73.33

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About PGY Pagaya Technologies Ltd.

Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.

Share on Social Networks: